Healthcare products company Johnson & Johnson (J&J) (NYSE:JNJ) announced on Thursday that new data from the Phase 3 MARIPOSA study will be presented at the 2025 European Lung Cancer Congress (ELCC).
The study shows that RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) significantly improved median overall survival by more than one year compared to osimertinib in first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or L858R mutations.
Yusri Elsayed, M.D., Ph.D., Global Therapeutic Area Head, Oncology at Johnson & Johnson Innovative Medicine, said that the new data will transform treatment discussions and patient expectations. Henar Hevia, Ph.D., Senior Director, EMEA Therapeutic Area Lead, added that the chemotherapy-free regimen represents an innovative and life-extending option for patients.
Additional presentations will include data from the Phase 2 COCOON study evaluating a preventative dermatologic regimen, which met its primary endpoint and improved patient experience. The Phase 2 PALOMA-2 study, assessing the feasibility of switching to subcutaneous amivantamab, will also be highlighted.
Blue Earth Therapeutics initiates Phase 2 trial in metastatic castrate resistant prostate cancer
TransCode Therapeutics reports progress in metastatic cancer trial
Ingenium Therapeutics' Gengleucel to enter Phase 2 trial in MRD+ AML following FDA feedback
AllyGPO and BioCareSD advance community oncology through integrated, tech-driven drug management
Nuformix receives positive EMA opinion for orphan drug designation of NXP002 in IPF
Atossa Therapeutics secures new US patent for proprietary (Z)-endoxifen formulations
Myosin Therapeutics receives grant to advance MT-110 clinical trial in methamphetamine use disorder
Bayer launches Phase I trial of targeted alpha therapy for advanced liver cancer
Oramed Pharmaceuticals invests in and collaborates with Alpha Tau Medical
House Rx launches AI-enabled pharmacy management platform
Avacta Therapeutics reports positive Phase 1 data for lead candidate
Portage Biotech advances PORT-7 to clinical trial after positive mesothelioma preclinical results
Oncoinvent reports positive 18-month Phase 1 data for Radspherin in ovarian cancer trial